ChemAbout
© 2026 ChemAbout
인사이트|개인정보 처리방침|이용약관|[email protected]
홈/화합물/원료의약품/Glucagon-like peptide II (human)
C171H266N48O56S
3922 g/mol
원료의약품

Glucagon-like peptide II (human)

CAS99120-49-7
용도 분류
원료의약품
화합물 분류
펩타이드
주요 용도
의약 원료

Glucagon-like peptide II (human) is a peptide compound that functions as a glucagon-like peptide 2 analog. It is used in pharmaceutical manufacturing as a synthetic peptide for research and development applications.

pharmaceutical raw material for peptide synthesislaboratory reagent for metabolic research

콘텐츠 범위: 이 페이지의 정보는 화학물질 식별 및 산업 공급·연구개발·제조 맥락을 대상으로 합니다. 치료 효능 주장, 의료 조언 또는 의약품 사용 지침에 해당하지 않습니다.

이 화합물을 구매하거나 공급하시겠습니까?

재고를 등록하거나 구매 요청을 게시하세요

CAS 99120-49-7

이 제품 등록하기
로그인 후 공급 정보 게시
이 제품 구매 요청
가입 없이 요청 제출

관련 화합물

강한 관련구조 유사유사도 0.98

GLP-2 (rat)

CAS195262-56-7

research compound

강한 관련구조 유사유사도 0.87

Teriparatide acetate

CAS99294-94-7

active pharmaceutical ingredient

강한 관련구조 유사유사도 0.87

테리파라타이드

CAS52232-67-4

active pharmaceutical ingredient

강한 관련구조 유사유사도 0.86

(Des-Thr5)-Glucagon Trifluoroacetate

CAS1802078-27-8

research compound

참고동일 카테고리

Lymecycline

CAS992-21-2

active pharmaceutical ingredient

참고동일 카테고리

네비보롤

CAS99200-09-6

active pharmaceutical ingredient

참고동일 카테고리

Erythromycin A 6,9-Imino Ether

CAS99290-97-8

antibiotic active pharmaceutical ingredient

참고동일 카테고리

(2R)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol

CAS99291-24-4

active pharmaceutical ingredient

식별자
IUPAC 이름

(4S)-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S,3S)-1-[[(2S,3R)-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoic acid

InChIKey

GMSOBKLEMFCAKA-GHAFJTHLSA-N

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC5=CNC=N5)N

동의어 목록 (2)

—